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ABSTRACT
USING GATORADE® TO CONTROL SERUM SODIUM LEVELS OF PATIENTS WITH
HYPONATREMIA
Hannah E. Degen, M.S.
School of Family, Consumer and Nutrition Sciences
Northern Illinois University, 2016
Josephine Umoren, Thesis Director

Background: Hyponatremia is a condition in which serum sodium levels are less than 135
mmol/L. It is the most prevalent sodium disorder in hospitalized patients. Currently, the most
commonly used treatment for the condition include fluid restriction, carefully monitored
hypertonic IV solution and diuretic therapy. In athletes with hyponatremia, low serum sodium
levels have been corrected with the administration of an isotonic beverage. Therefore, giving
Gatorade® to patients with hyponatremia may be an alternative treatment method to increase
serum sodium levels.
Objective: The purpose of the study was to examine the effect of oral Gatorade® protocol on
serum sodium levels of hospitalized elderly patients with hyponatremia.
Methods: In this randomized control experimental study, subjects were randomly assigned to the
experimental (n=15) or control group (n=15). Ten participants were on a fluid-restricted diet; 20
participants did not have a fluid restriction. In the experimental group, there were five
participants on fluid restriction and ten participants not on a fluid restriction. The same
composition was found in the control group. The participants were enrolled in the study for
seven days. Over those seven days, the participants in the fluid restriction were given water or
Gatorade® with their medicine. Participants not on a fluid restriction were given 4 oz. of water

or Gatorade® at each meal. Serum sodium levels were tested before and after the study. The
foods and beverages consumed during the study were documented and total sodium consumed
was calculated. The hypothesis was tested using ANOVA and paired-samples t-test.
Results: The results of this study found there was not a significant difference between serum
sodium levels of patients with hyponatremia who were given Gatorade®, as compared to water,
when not on a fluid-restricted diet. There was a significant difference (p < .05) between pre- and
post-test serum sodium levels in non-fluid-restricted participants consuming Gatorade® and all
participants on a fluid-restricted diet.
Conclusions: These results suggest that patients with hyponatremia who are not on a fluidrestricted diet may benefit from receiving Gatorade® with meals.
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CHAPTER 1

INTRODUCTION

Background
Disorders in water and sodium balance are a common finding among hospitalized
patients.1 Sodium is the principal extracellular cation and hyponatremia is a disorder in which
plasma sodium concentrations are less than 135 mmol/L, characterized by decreased osmolality.
Normal serum sodium concentration levels range between 135-144 mmol/L.2
There are multiple causes for development of hyponatremia, including fluid imbalance,
kidney disorders, and impaired hypothalamus thirst center. Alterations in sodium and water
balance affect the central nervous system. Hyponatremia is a potentially life-threatening disorder
that can contribute to neurological problems including dizziness, lethargy, seizures, and coma.
Early diagnosis and treatment can prevent complications of hyponatremia.3
Studies have shown that mild hyponatremia can have long-lasting consequences. These
include deficits in gait and attention, falls, decreases in bone density, and fractures. These effects
are especially prevalent in the elderly.4-8 Adults with hyponatremia have been found to present
with significantly lower bone mineral density and an increased prevalence of osteoporosis.6
There is a significant increase in length of stay for hospitalized patients with hyponatremia.9
There are also significantly higher morbidity and mortality rates associated with hyponatremia.

2
10-11

The consequences of hyponatremia can result in adverse effects in both hospitalized patients

and otherwise healthy individuals.
Older adults have an increased risk of hyponatremia due to degenerate physiology,
multiple co-morbidities, increased risk of dehydration, and stress from fracture and surgical
interventions.12 They are at an increased risk for fluid and electrolyte imbalances due to their
compromised renal and water-conserving ability as well as their impaired thirst mechanism,
which decreases their fluid consumption.13
Patients hospitalized with hyponatremia can be treated with several different
mechanisms. One method of treatment is the use of diuretic therapy to reduce body fluid content
by inhibiting the antidiuretic hormone (ADH), which results in increased fluid loss via the
kidneys. A fluid-restricted diet is another common method used to treat hyponatremia among
patients. This method is used to reduce edema and to prevent further dilution of serum sodium
levels.14
Exercise-associated hyponatremia is induced by excessive fluid consumption while
exercising, not for medical reasons. Exercise-associated hyponatremia is most commonly found
in athletes who participate in ultra-endurance events. It is a result of excessive fluid intake,
increased retention of fluid, elevated sweat sodium loss, and an impaired glomular filtration
rate.15
The use of isotonic beverages comprised of sodium, glucose, and potassium has been
shown to help athletes better maintain their serum sodium levels and prevent hyponatremia.
Glucose, electrolytes, and water stores need to be replenished when exercising to prevent
depletion and dehydration. When the stores are not replenished, the athlete is at increased risk for
hyponatremia. Athletes who drink isotonic solutions have been shown to replenish body stores
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more quickly than athletes who drink water alone.16 The isotonic beverage appears to help better
control their serum sodium levels and prevent hyponatremia. Therefore, it is proposed that
elderly patients with hyponatremia may normalize their serum sodium levels earlier when
provided an isotonic beverage.

Statement of the Problem

Evidence indicates drinking an isotonic beverage increases athletes’ serum sodium levels.
However, this has not been explored in hospitalized patients with low serum sodium levels. This
study investigated the effect of Gatorade® consumption on serum sodium levels among patients
on both fluid-restricted and non-fluid-restricted diets.

Independent Variable
Fluid intake: Gatorade® (experimental) or plain water (control).

Dependent Variable
Serum sodium levels

Hypotheses

The following hypotheses were investigated:
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1.

Elderly patients with hyponatremia on a fluid-restricted diet will have

significantly higher serum sodium levels when given Gatorade® compared to those
patients on the standard treatment protocol.
Independent Variable: Fluid intake: Gatorade® or water
Dependent Variable: Serum sodium level
2.

Elderly patients with hyponatremia not on a fluid-restricted diet will have

significantly higher serum sodium levels when given Gatorade® compared to those
patients on the standard treatment protocol.
Independent Variable: Fluid intake: Gatorade® or water
Dependent Variable: Serum sodium level
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CHAPTER 2

REVIEW OF LITERATURE

Introduction
Hyponatremia is a medical condition in which serum sodium levels are below 135
mmol/L, whereas normal serum sodium levels range between 135-144 mmol/L.2 Hyponatremia
is caused by various conditions including fluid imbalance, kidney disorders, and impaired
hypothalamus thirst center. Without intervention, hyponatremia can lead to neurological
problems. Individuals at greatest risk for hyponatremia are the elderly, individuals with kidney
disorders, impaired thirst mechanisms, and fluid overload.
Other causes of hyponatremia may not be due to medical reasons; such is the case with
athletes. When athletes drink an excessive amount of water they may experience fluid overload,
which could lead to hyponatremia. Older adults are at an increased risk for fluid and electrolyte
imbalances due to their compromised renal and water-conserving ability as well as their impaired
thirst mechanism, which decreases their fluid consumption.13
The consequences of hyponatremia can result in adverse effects in both hospitalized
patients and otherwise healthy individuals. Hospitalized patients with hyponatremia tend to have
significantly longer hospital stays than non-hyponatremic patients.9 There are also significantly
higher mortality rates associated with hyponatremia.10 Hyponatremia may result in neurological
problems such as cerebral edema or brain cell swelling and herniation of the brain stem leading

6

to permanent brain damage. Adults with hyponatremia have been found to present with
significantly lower bone mineral density and an increased prevalence of osteoporosis.6 When
hyponatremia is treated too rapidly, it may increase risk of osmotic demyelination and permanent
neurologic deficits. Therefore, early diagnosis and treatment are crucial for correction and
prevention of brain damage.
There are currently several approaches used to treat patients hospitalized with
hyponatremia. One common practice is the use of fluid restriction diet prescriptions for patients
with hyponatremia. Fluid restrictions are used to minimize and reduce edema and to prevent
further dilution of the serum sodium levels. Another treatment is the use of diuretic therapy in
those with hyponatremia so as to reduce body fluid content by inhibiting the antidiuretic
hormone (ADH), which results in increased fluid loss via the kidneys.14
A technique that has proved to be successful in the prevention of hyponatremia in healthy
athletic individuals is the use of specially designed isotonic beverages. Isotonic beverages are
sports drinks that contain both sodium and glucose to help replace water and electrolytes. The
use of isotonic beverages comprised of sodium, glucose, and potassium have been shown to help
athletes better maintain their serum sodium levels. Such beverages are consumed in accordance
to the type of activity and the environmental conditions. When engaged in physical activity, the
body uses electrolytes, glucose, and water stores that must be replenished to prevent depletion
and dehydration. If stores are not replenished the individual is at increased risk for hyponatremia.
Athletes who drink isotonic solutions replenish body stores more quickly than athletes who drink
water alone.16 This helps to better control their serum sodium levels and prevent hyponatremia.
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Sodium
Normal adult serum sodium levels are between 135-144 mEq/L.2 Sodium is the main
cation in the extracellular fluid and thus is important in maintaining fluid retention in the body. It
makes up about 93% of the cations in the body.17 A reduction in the serum sodium concentration
in the extracellular fluid may be due to an increase in the water in the extracellular fluid or a
decrease in the sodium content in the extracellular fluid.18 Sodium works to maintain plasma
volume and osmolality19.
When serum osmolality is low, osmosis shifts the fluid out of the extracellular fluid space
into the intracellular fluid space to increase the serum osmolality. This shift in fluid results in the
swelling of the cells. The brain is very susceptible to the changes in body fluid volume because it
has a limited ability to expand. The brain cells will expand when there is a drop in serum sodium
levels. This is due to the fact that the brain cells do not have time to adapt to the extracellular
fluid hypotonicity and therefore swell, leading to neurological damage or death.20
On the other hand, hypernatremia occurs when serum sodium concentration increases
above 144 mmol/L due to a net fluid loss and/or an increased retention of sodium in the body. In
hospitalized patients, the causes may include intravenous infusion of hypertonic saline, excessive
salt ingestion, and bicarbonate administration during cardiac arrest. Patients with hypernatremia
may have neurological complications or death if untreated.10
Sodium concentrations in the body’s plasma are maintained by homeostasis within a
narrow range. The mechanisms involved include thirst, ADH, aldosterone, and renal control of
water excretion.
The kidneys regulate extracellular fluid volume and blood pressure by the reninangiotensin-aldosterone system.17 When there is a decrease in blood pressure or plasma sodium
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levels the kidneys activate the system. Renin is secreted by the granular cells in the
juxtaglomerular apparatus. Renin hydrolyzes angiotensinogen into angiotensin I. Angiotensin I is
then converted into angiotensin II.17 Angiotensin II acts as a vasoconstrictor which reduces the
glomerular filtration rate and the filtered load of sodium. Angiotensin II also stimulates the
release of aldosterone from the adrenal cortex. Aldosterone increases sodium reabsorption in the
renal tubules by increasing the sodium channels and Na+-K+ pumps. This causes an increase in
water and salt reabsorption and increases blood pressure.21
Sodium concentrations play a role in maintaining the electrical gradients across cell
membranes. Sodium also interacts in nerve impulse transmissions and muscle excitation through
the Na+/K+-ATPase pump. In this pump, sodium is exchanged for potassium, which causes the
hydrolysis of ATP. The electrochemical potential gradient causes an impulse or nerve
conduction.17
When a large amount of fluid is consumed, hypo-osmolality occurs, which stimulates
osmoreceptors to decrease the release of ADH from the pituitary gland. The decreased ADH
secretion results in an increase in the permeability of renal tubular cells to water. The water is
reabsorbed from the collecting ducts and distal tubules of the kidneys and returned to the
circulation, thereby causing hyponatremia.21

Hyponatremia
Normal serum sodium concentration is 135-144 mEq/L.2 Hyponatremia results when
serum sodium concentration falls below 135 mmol/L.22 The condition occurs when there is an
excess of fluid in relation to sodium stores in the body.23 Hyponatremia is the most common
electrolyte disorder in clinical practice. Mild hyponatremia (serum sodium concentrations of
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130-135 mmol/L) occurs in 15-30% of hospitalized patients.22 If hyponatremia is left untreated,
it can cause neurological issues. Hyponatremia treated too rapidly can cause significant risk for
osmotic demyelination and permanent neurologic deficits.23
Hyponatremia occurs due to disruption of fluid and sodium homeostasis. This balance is
usually maintained by multi-system mechanisms in the body. The serum osmolality is affected
by water intake and the renal clearance of water.20 When the excretion of fluid by the kidney is
impaired, it results in increased retention of fluid in circulation; this causes the serum sodium
levels in the body to become diluted.
The kidneys are an important system in the regulation of sodium. Low sodium levels may
be due to the glomerular filtration rate being low. The capillaries in the glomerulus filter water
and electrolytes from the plasma. This allows the kidneys to regulate fluid and electrolyte
homeostasis. In a healthy kidney, a change in fluid and electrolyte intake would cause the
volume and constituents of the urine to vary.17 Having a low glomerular filtration rate would
decrease the water excretion. The glomerular filtrate needs to be adequately delivered to the
renal tube in order for the urine to be diluted.24
Another important function of the kidneys is the reabsorption of sodium in the distal
tubule. ADH must be present for the reabsorption of water from the renal tubule into circulation.
ADH increases the permeability of water in the collecting ducts.24 The increase in water can
decrease the osmolarity of the blood. The posterior pituitary also has to regulate ADH secretion
in response to serum osmolality.13 A decrease in serum osmolality causes ADH secretion to stop.
Impaired kidney functions can lead to failure to excrete water or inappropriate reabsorption of
water, which would cause serum sodium levels to decrease.
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Other causes of hyponatremia include diseases, pharmacotherapy, and pathophysiological
variations. Patients taking medications including thiazide diuretics, chemotherapeutic agents, and
psychotropic agents may develop hyponatremia.2 Heart failure, renal disease, thyroid disease,
adrenal insufficiency, and cirrhosis are some of the diseases associated with hyponatremia.13
Kidney failure is associated with hyponatremia. In this condition, the excretion of water
by the kidney is impaired, which causes retention of water in blood circulation. The increased
water dilutes serum sodium levels.13 Advanced cirrhosis can impair the kidney’s ability to
eliminate solute-free water. This causes water retention and decreases the serum sodium
concentration, which results in hyponatremia and hypo-osmolality.25
Hyponatremia occurs in roughly 20% of patients admitted with heart failure.9, 26-28
Patients with heart failure have increased hormones including renin, norepinephrine, and ADH
levels. This is due to a decrease in blood pressure and cardiac output.29 The increased hormones
impair the body’s ability to excrete water. Hyponatremia in heart failure patients may also be due
to the diuretic therapy used to manage the disease. The diuretics cause renal sodium loss and
therefore decrease the body’s sodium levels.9
Euvolemic hyponatremia is associated with urine sodium greater than 30 mEq/L and is
the result of an increase in the total body water with a small change in serum sodium. It usually
occurs with nonosmotic ADH secretion (syndrome of inappropriate ADH hormone release
[SIADH]). This happens when there is continued release of ADH even though there is low serum
osmolality in the body. ADH controls renal clearance of water and water intake. It causes
reabsorption of water and urination.20 ADH secretion stops when plasma sodium is ˂135 mEq/L;
35% of patients with hyponatremia have SIADH.30 In most cases of SIADH, advanced age is a
significant risk factor for the development of hyponatremia.
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Hyponatremia in Athletes
Athletes may experience hyponatremia due to an excessive water intake, which results in
fluid overload. The increased fluid causes dilutional hyponatremia. For shorter distances, the
American College of Sports Medicine recommends a fluid intake of 0.6-1.2 l/h (20.3-40.6 oz.
/h). Although it can be difficult to make a recommendation because everyone has different water
loss and weather conditions affect the amount of water the body needs.31
If no fluid is consumed when exercising, the plasma sodium concentration and osmolality
increase depending on the loss of electrolytes and water in sweat. The plasma osmolality
increases because less sodium is lost in sweat than water. The water lost in sweat can either be
from the extracellular fluid or the intracellular fluid. When athletes consume water or sports
drinks of up to 25 mEq Na+ l-1 in volumes that match the rate of fluid lost in sweat, their plasma
sodium and osmolality decrease at similar rates.32
Males retained significantly more fluid when given drinks with increased sodium
concentration. In addition, the blood and plasma volumes increased after drinking higher sodium
drinks.33 A different study found a carbohydrate and sodium drink had a significant effect on
excretion of electrolytes and water in urine. The higher sodium intake decreased the urine
volume and increased the urinary sodium loss.32 In addition, female participant’s beverages with
sodium had a significantly higher serum sodium concentration than participants given beverages
without sodium.34
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Osteoarthritis and Hyponatremia
In most instances patients with hyponatremia are significantly older (mean age of 67.8),
have a lower bone mineral density and an increased prevalence of osteoporosiss.6 In the US,
there are approximately 30-50 million people with osteoporosis. Osteoporosis is a disease in
which there is deterioration of bone tissues and low bone mineral density. This increases the risk
for fractures due to fragile bones.17
A study of 1,408 female patients who underwent bone mineral density measurements
found patients with hyponatremia (serum sodium less than 135 mmol/L) had a 2.86-increased
odds ratio of having a fracture occur compared to patients without hyponatremia. In patients with
a fracture, 8.7% of them had hyponatremia while 3.2% of patients with hyponatremia did not
have a fracture.6
Renneboog et al. matched 122 elderly patients (72±13) with falls to 244 control patients.4
The results showed the patients with hyponatremia (serum sodium between 115-132 mEq/L)
experienced falls at a rate of 21% compared to 5% of patients without hyponatremia. The same
authors found an increase in falls with patients who have chronic hyponatremia compared to
patients without hyponatremia.4
One animal study found mild hyponatremia is associated with increased risk of
osteoporosis at the hip.7 In rats with SIADH having hyponatremia for three months significantly
decreased bone mineral density by 30%. There was also a decrease in cortical bone and
trabecular bone due to increased bone resorption and decreased bone formation. Hyponatremia
also stimulated osteoclasogenesis and resorptive activity which causes resorptive osteoporosis.8
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Elderly patients with fractures have an increased risk of hyponatremia due to their
degenerate physiology, increased risk of dehydration due to hospitalization, homeostatic stress
from the fracture, and multiple co-morbidities.12

Hyponatremia in Elderly
The elderly have an increased risk for electrolyte and fluid imbalances because of
impaired renal sodium and water-conserving ability as well as decreased sensitivity to thirst. The
elderly have lower glomerular filtration rates. This can cause a decrease in the delivery of filtrate
to the distal tubule and decrease the water excreted.13, 24 Having a low glomerular filtration rate
would decrease the water excretion. They may also be taking medications that impair the distal
tubules ability to reabsorb sodium from the urine. Elderly patients may have increased levels of
ADH, which would cause an increase in water reabsorption. This is because ADH secretion
increases the permeability of water in the collecting ducts.24 They may have a comorbid
condition (heart failure, renal disease, thyroid disease, cirrhosis, adrenal insufficiency) which is
associated with the development of hyponatremia.13
Renal and other age-related physiological changes increase the sensitivity of older adults
to dehydration. Dehydration can cause impairment of physical and cognitive performance. As a
person ages there is a decrease in lean body mass leading to an increase in the ratio of
extracellular to intracellular fluids. This causes the total amount of water in the body to decrease
by 10-15%. The thirst mechanism in older adults may also be impaired due to hormonal changes,
this would decrease fluid intake.35 If the hypothalamus thirst center does not register that a
person needs fluid due to an increase in extracellular fluid osmolality or decrease in blood
volume, then they will not feel thirsty.17 This will decrease the amount of fluid consumed.
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Older adults have an impaired sensitivity to thirst, which can cause dehydration. Older
men (ages 54-70 years) rated carbohydrate-electrolyte solutions (6% carbohydrate and 18.0
mmolL-1 NaCl) as having a better flavor and higher overall acceptance than water. Older women
(ages 54-70 years), on the other hand, rated water as having a better flavor, aftertaste, and overall
acceptance than a carbohydrate-electrolyte solution.36 The total fluid intake of carbohydrateelectrolyte solution was significantly higher in both males and females than water. The plasma
volume was at or above baseline for all subjects when consuming carbohydrate-electrolyte
solution. The subjects were put on a cycle ergometer and cycled at an intensity of 65± 1% of
VO2 for 15 minutes followed by 15 minutes of rest, at which time subjects were allowed to
drink. This was continued until the subject had completed four 15-minute bouts of cycling and
four 15-minute rest periods. The subjects were given a 700 mL bottle of fluid (either water or
carbohydrate-electrolyte solution) randomly assigned. The volume of fluid intake was measured
after rest periods 1-3 and recovery. The subjects were not aware their fluid consumption was
being measured. When exercising, the participants drank enough fluid to match their sweating
rates.36
In older adults, there is a decrease in renal mass caused by glomerular loss. This inhibits
the kidney’s ability to retain sodium and water. The kidney’s tubular function and medullary
concentration gradient are impaired, which decreases the kidney’s ability to concentrate urine
and control water and electrolyte balance.35 This causes an increased risk for hyponatremia.

Mortality Rates
Low serum sodium levels in patients are associated with increased mortality rates.37-38
Patients with hyponatremia (serum sodium less than 135 mEq/l) have significantly lower

15

survival rates when admitted to the hospital than patients without hyponatremia. A cohort study
of 3,551 patients in an ambulatory setting found there is a two-fold increase in risk of death even
when adjusting for major risk factors (age, diabetes, CKD, cirrhosis, use of diuretics, and a
history of cancer) when a patient has hyponatremia.10
Patients admitted with hyponatremia (serum sodium less than 135 mEq/L) have a 50%
increased risk of death than patients with normal serum sodium levels.2 A prospective cohort
study of 98,411 patients hospitalized in Boston, Massachusetts, found patients with
hyponatremia have an increased death risk during their hospital stay as well as at 1-year and 5year follow-ups than patients without hyponatremia. At the 5-year follow-up, patients admitted
with serum sodium levels of 130-140 mEq/L had an increased risk of death of 24%, patients at
125-129 mEq/L had a risk of death of 33%, and patients serum sodium if 120-124 mEq/Lv had a
29% increased risk of death.2 Another cohort study with 53,236 hospitalized patients found
patients with hyponatremia had a higher percentage of co-morbidities (heart failure, chronic
kidney disease, diabetes, liver disease, dementia) and were associated with more severe
diseases.39
Hyponatremia is associated with ascites, hepatorenal syndrome and death from liver
disease. In patients on the liver transplant wait list, a decrease in the serum sodium levels is
associated with an increased risk of death. Serum sodium levels between 125-140 mmol/L had
the biggest effect on mortality in patients with hyponatremia. There was a 5% increase risk of
death per unit decrease in the serum sodium concentrations between 125-140 mmol/L. A study
examining 13,940 patients on the wait list for a liver transplant found patients with hyponatremia
(serum sodium between 125-140 mmol/l) had increased morbidity and mortality during the
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postoperative period.40 Hemodialysis patients (age 58 ± 13 years) who have a lower serum
sodium level (≤138.4 MMOL/l) have a significantly poorer survival rate.41
Patients admitted for musculoskeletal surgery, metastic cancer, or cardiovascular disease
have an increased risk of in-hospital mortality when admitted with hyponatremia.2 A study
examining acute ST-elevation myocardial infarction in 978 patients found patients with acute
ST-elevation myocardial infarction and hyponatremia (serum sodium less than 136 mEq/L
during the first 72 hours of hospital stay) had an increased probability of death during the 31month follow up. There was also an increased probability of heart failure during follow-up in
patients admitted with hyponatremia.42
Hyponatremia is also associated with prolonged length of hospital stay.9, 39 A study of
2,880 patients with a mean age of 78.6 ± 6.98 found patients with hyponatremia (serum sodium
≤131 mmol/l) have a significantly longer hospital stay (19.8 ± 8.3 days) compared to patients
without hyponatremia (16.8 ± 8.9 days).43 In a cohort study of 964,263 adults undergoing major
surgery, patients with hyponatremia (serum sodium less than 135 mEq/L) who underwent an
operation had a longer length of stay by a median of one day.44
Lower serum sodium levels is an independent predictor for higher risk of infectionrelated hospitalization in patients with hemodialysis. One study with 332 patients with end-stage
renal disease found hyponatremia might result in an increased susceptibility to infection and
infectious disease, which contributes to mortality. There was a significant association between
low serum sodium levels and an increased risk of infection-related hospitalization. The study
also found there was a significant association between low serum sodium levels and mortality.45
Patients with preoperative hyponatremia are also at increased risk for infection and pneumonia.44
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Hyponatremia before liver transplant has been associated with adverse post-transplant
outcomes. Liver transplant patients with low values of pre-transplant serum sodium had an
increased risk of death. A study done on 318 liver transplant patients found patients with
hyponatremia (serum sodium ≤ 130 mEq/L) have a shorter survival time 1, 5, and 10 years after
liver transplant compared to normonatremic (serum sodium greater than 130 mEq/L) patients46.
Post-transplant patients with cirrhotic hyponatremia had an increased risk of infection,
neurological, and renal disorders than normonatremic patients.47 Another study found that a
patient with liver disease had a significant increase in risk of death for patients with serum
sodium concentrations of 120-124 mEq/L.2

Treatment of Hyponatremia
The treatment of hyponatremia depends on the underlying cause. Treatments include
fluid restriction, saline solution, and diuretic therapy.14 The rate at which serum sodium levels
are corrected is important in treating hyponatremia. If the pace is too rapid it can create a risk for
osmotic demyelination syndrome and lead to permanent neurological deficits.23 Osmotic
demyelination syndrome causes cells to shrink. Therefore, a patient’s sodium levels should be
monitored carefully to ensure hyponatremia is not being corrected too quickly.
Patients with hypovolemic hyponatremia cannot have intravenous fluids because it would
increase the volume overload. It also cannot be used in patients with SIADH because it will
cause more retention of free water. Isotonic saline may be given if it is unclear if a patient is
volume depleted or has SIADH. In elderly patients, volume status may be difficult to tell, in
which case giving isotonic saline would help determine the volume. If the patient’s sodium
levels improve after a small dose of saline is given, the intravenous fluids should be continued
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because the diagnosis is usually volume depletion. If the patient’s sodium levels fall, the
intravenous fluids should be discontinued.13
Patients with symptomatic hyponatremia are usually given hypertonic saline (3% sodium
chloride). This causes a rapid rise in serum sodium and resolution of neurological symptoms. To
determine the infusion rate of hypertonic saline, the Androgue-Madias formula may be used. For
every 1L of infused solution, the change in serum sodium is

( Na  K ) inf used  serumNa
.
totalbodywater(l )  1

This formula does consider the body a closed system and does not take into account the urinary
losses of potassium and sodium13.
Patients may be given demeclocyline an antibiotic that inhibits AVP. It is not FDA approved
for the treatment of hyponatremia. The correction rate is generally slow taking 2-3 days before
an effect is seen. It is used sparingly because it has significant nephrotoxic potential in cirrhotic
patients.13
Loop diuretics can help manage the fluid volume of patients with hyponatremia. Patients
with volume overload and severe hyponatremia may be given hypertonic saline and loop
diuretics to help manage their fluid volume. They may also increase water excretion because it
inhibits hypertonic medullary gradient needed for water reabsorption.13
AVP receptor antagonists compete with AVP for the vasopressin type 2 receptor and block
AVP to increase free water absorption. It causes a rise in serum sodium levels. Patients given
AVP receptor antagonists have to be monitored for their serum sodium levels because it is
difficult to predict the correction rate of serum sodium levels.13
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Fluid Restriction
Treatment of hyponatremia by fluid restriction is considered the standard of care by many
physicians.48,49 Compared to no treatment, the use of a fluid restriction decreased the time of
resolution of hyponatremia.50 The recommended fluid restriction is < 1L per day of fluid over the
daily urinary volume.51 Fluid restriction is used to decrease water in the body. If the water intake
is limited, then water excretion should be greater than water intake. This will cause a decrease in
fluid in the body and increase serum sodium osmolality.13
Patients on a fluid restriction need to have their fluid balance assessed. If the fluid volume
given in excess of the fluid lost in the urine, it will lower the serum sodium levels. Therefore, the
assessment of urine-free water losses and nonrenal free water loss is needed. The urine-free

  urinesodium  potassium 


plasmasodium


.
water loss can be estimated by freewaterloss  urinevolume1  






A randomized control trial of 64 patients found patients given a stricter fluid restriction
(1,000 mL/d) after being discharged had a higher quality of life after 60 days compared to the
usual-care group (given discharge instructions and education).52 This may be due to the control
of serum sodium levels and not the actual fluid-restricted diet. The patients who had a
conservative dietary sodium intake, 1,000 mL/d fluid restriction, and high diuretic dose had
significantly better outcomes at 6 months than other groups.50 Other studies have found being on
a fluid-restricted diet negatively affects a patient’s quality of life.53-54
Studies have found successful fluid restriction can raise serum sodium levels up to 3
mEq/L.55-56 In order to be efficient, fluid restrictions require patient compliance. The
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hyponatremia registry found out of 1,524 participants, 48% were treated with fluid restriction.
The study found participants on a fluid restriction had a modest increase in serum sodium level
with a median rate of 2.0 mEq/L/d.55

Sports Drinks
During exercise the body uses electrolytes, water, and glucose stores to replenish the
muscle and liver depletion. The use of these stores may lead to dehydration. Using isotonic
solutions to replenish these stores can allow the body to maintain homeostasis.16
Isotonic beverages are composed of sodium, glucose, and potassium. If the amount of
carbohydrates in a beverage is increased, it leads to a decrease in the delivery of fluids
throughout the body. When there is a high concentration of carbohydrates in the intestine, it
causes water to move out of the body and into the lumen of the intestine. This can increase the
effects of dehydration because the water is leaving body stores and moving into the intestine
depleting the body of more water.
One study found that males given a beverage with glucose content above 6% had a
decrease in fluid delivery compared to when they were given water.57 The same study found that
increasing the sodium content of the beverage had no effect on the fluid delivery.57
Another study of 15 men age 19-49 years (34.4±10) found having a 12% carbohydrate
fluid with electrolytes had a greater fluid retention than water and water with electrolytes. An 8%
carbohydrate and higher beverage emptied more slowly from the intestine and decreased the
intestinal fluid uptake. A 12% carbohydrate beverage caused an increase in plasma glucose,
which increased the plasma osmolality and stimulated vasopressin, insulin, and renin. The
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increase in insulin would cause an increase in sodium reabsorption. These responses may have
caused the increase in fluid retention for the 12% carbohydrate beverage.19
The World Health Organization recommends a 90 mmol/l sodium and 11 mmol/l glucose for
the treatment of dehydration induced by diarrhea. The solution is used to help with fluid
absorption by the intestinal sodium-glucose cotransporter.19
Studies have found isotonic beverages help to decrease the decline in serum sodium
levels. One study found participants given a carbohydrate-electrolyte beverage during exercise
had a decrease in the decline in serum sodium from pre- to post-exercise compared with
beverages that do not contain sodium.18 Another study found consuming a beverage that
contains a moderate amount of sodium (19.9 mmol/L) at a rate equal to body mass change
helped to reduce the decrease in the plasma sodium concentrations as well as preserve the plasma
volume during exercise.58
Giving athletes Gatorade® compared to water significantly increased their maximal
exertion time.59 This suggests that Gatorade® may be able to rehydrate better than water. The
degree of dehydration in the athletes was less when drinking Gatorade® compared to water.

Conclusion
Hyponatremia is the most common electrolyte disorder among hospitalized patients. It
increases patient hospitalization time and mortality rates.10,11 Research shows that beverages with
a higher sodium content have decreased the decline of serum sodium levels in athletes compared
to beverages with lower sodium concentration.19,57-59 Pursuing this further is important to
determine if isotonic beverages can be used as an alternative treatment for hyponatremia in
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hospitalized patients. The purpose of this study was to determine if Gatorade® increased serum
sodium levels in patients with hyponatremia.
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CHAPTER 3

METHODS

Experimental Design
The study was a randomized experimental control design. Participants were divided into
two groups according to their diet prescription upon admission: fluid restriction or non-fluid
restriction. Within each diet prescription the participants were placed in either the control group
or the experimental group. The participants in the control group on a fluid restriction were given
the standard protocol of water to take with their medicine, while the control group participants
not on a fluid restriction were given 4 oz. of water on each meal tray (Table 1). The participants
in the experimental group not on a fluid restriction were given 4 oz. of Gatorade® with each
meal tray. The experimental group on a fluid-restricted diet were given Gatorade® to take with
their medicine. All participants in the fluid restriction group were given either water or
Gatorade® ranging from 9.3-18.6 oz. per day to take with their medicine, depending on the
prescribed fluid restriction (Appendix A).
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Table 1. Experimental Design
Diet Prescription

Control Group

Experimental Group

Non-Fluid Restriction

Given 4 oz. of water with

Given 4 oz. of Gatorade®

each meal

with each meal

Given prescribed amount of

Given prescribed amount of

water to take with medicine

Gatorade® to take with

(Ranging from 9.3-18.6 oz.

medicine (Ranging from 9.3-

per day)

18.6 oz. per day)

Fluid Restriction

Participants
Subjects were recruited by the registered dietitians assigned to the floors on which the
attending physicians assented for the study. Subjects for this study were recruited using a
convenience sampling method at Marianjoy Rehabilitation Hospital (Marianjoy), a physical
rehabilitation hospital. All participants in this study were diagnosed with hyponatremia (serum
sodium less than 135 mmol/L). Individuals were eligible to participate if they had hyponatremia,
were being treated for hyponatremia, and were between the ages of 60-85 years old. Treatment
for hyponatremia in this facility included a fluid-restricted diet ranging from 1000 ml-2000 ml
per day (Appendix A) or a non-fluid-restricted diet. Individuals on a renal diet were excluded
from the study because their diet prescription limited their sodium intake to less than 2,400 mgs
per day. In addition, individuals with cognitive disorders including dementia, Alzheimer’s
disease and organic brain syndrome were excluded from the study because they could not give
consent to participate in the study.
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Originally all subjects with a hyponatremia diagnosis in this facility had been prescribed
a fluid-restricted diet. The fluid restriction regimens ranged from 1000 ml-2000 ml per day, the
standard protocol for the facility, and were prescribed by the attending physicians. However, due
to the low facility census and lack of patients prescribed fluid-restricted diets, the study protocol
was modified to include patients with hyponatremia not on fluid restriction diets with IRB
approval (Appendix B).
Prior to enrollment in the study, the primary researcher explained the study requirements
to potential participants. Participants were informed of confidentiality in participation of the
study. In addition, they were informed of the risks and benefits associated with this study and
were required to sign written consent (Appendix C, D) before participating in accordance with
the study procedures approved by the Marianjoy Rehabilitation Hospital Institutional Review
Board (IRB) (Appendix E). Subjects were also informed the study was voluntary and that their
decision to participate in the study would not affect their care at Marianjoy.

Data Collection
Participants’ fluid intake was monitored and recorded daily by the diet technicians and
the nursing staff. The fluid that the participants used to take their medicine with was documented
by the nursing staff in their medical records; any leftover fluids were put on the participants’
meal tray to be measured and recorded by the researcher. The fluids consumed with meals were
monitored and documented by the diet technicians as trained by the researcher. The diet
technicians documented all fluids and foods ordered by the patient in Computrition (2014), a
foodservice software used to track the foods and beverages patients receive from the hospital
kitchen.
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The researcher measured and recorded all leftover food from the participants’ plates after
each meal, to the nearest ounce, using the A&D SJ Series Digital Portion Scale. The leftover
fluid from the meals and medicine was measured using a C and A Scientific PL-C 250 plastic
250 mL cylinder to the nearest milliliter.
The participants’ demographic information was obtained from their individual medical
charts. This information included their age, gender, and ethnicity. In addition, the participants’
weight, fluid input and output, and the presence of pitting edema were recorded from the medical
charts. Medications and presence of confounding diseases such as diabetes, liver disease, or heart
disease were noted from the medical charts.
Prior to the study, subjects had their blood drawn by trained hospital phlebotomists
wearing medical exam gloves and lab coats. The phlebotomist drew one serum separator tube of
.7 mL whole blood. The clotted blood sample was centrifuged for 15 minutes at 3500 RPM
(model 642). The blood was separated into its components of plasma, red blood cells, and white
blood cells. The blood was stored in a refrigerator at 33.8-42.80F before it was sent to Central
DuPage Hospital for analysis. During transportation the blood was kept in a cooler at 33.942.80F. A minimum of 0.3 mL of serum or plasma was required in order for the serum sodium
test to be performed. The sodium was then measured using an indirect ion-selective electrode
potentiometer (Roche, Indianapolis IN).

Intervention
The participants in the experimental group received G2 lemon-lime flavor obtained from
PepsiCo Foodservice (55 West Monroe St, Chicago IL). The composition of the Gatorade® per
ounce is 0.5 g carbohydrates ( 1.63g sucrose, 0.15g glucose ), 18.75 mg sodium, 5.6 mg
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potassium (Appendix F). Gatorade® was selected for use in this study based on results from
sports nutrition research that show when there is a decrease in serum sodium levels among
healthy adults, consumption of Gatorade® helps to increase the serum sodium levels.19, 57-59

Statistical Analysis
Descriptive measures were used to describe the study population. One-way analysis of
variance (ANOVA) was used for inferential statistics. Within- and between-group differences in
sodium intake and serum sodium levels were analyzed using repeated-measures ANOVA.
ANOVA was used to determine if there was a significant difference between the serum sodium
levels of the groups. A paired-samples test was used to examine serum sodium levels pre and
post-study. Statistical significance for all data analysis was accepted at the p<0.05 level of
confidence. Data was analyzed by using the Statistical Package for Social Sciences (SPSS) for
Windows (Version 21.0, 2013, SPSS, Inc., Chicago, IL).
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CHAPTER 4

RESULTS

Characteristics of the Participants
Participant characteristics are shown in Table 2. A total of 32 patients consented to
participate in the study; however, two of the participants did not complete the 7-day study.
Therefore, 30 participants completed the study. Subjects ranged in age from 60-85 years of age,
with a mean age for all participants of 75.4+6.44, and were predominantly male (60%) (Table 2).
The majority of participants had hypertension (80%) while 5 out of 30 (16.67%)
participants had diabetes. Comorbidities are shown in Table 3.

Sodium Intake
The mean sodium intake from food for participants in the experimental group on a fluid
restriction was 3,115.4 ± 337.39mg per day. The mean total sodium intake from both food and
Gatorade® was 3,315.40 ± 327.60mg. Participants in the fluid restriction control group had a
mean sodium intake from food of 3,251.60 ±769.60mg. The non-fluid-restricted experimental
group consumed an average of 2,639.70 ± 678.21mg of sodium from their food for an overall
mean total of 2,798.70 ± 678.21mg sodium. The non-fluid-restricted control participants
consumed a mean sodium intake of 2,575.50 ± 994.91mg. The mean total sodium intake from
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food and Gatorade® per day was 3,166.31±493.58mg. The average mean sodium intake from
food of all participants was 2,982.83±491.06mg (Table 4). There was a statistically significant
difference (p<0.05) between sodium intake levels of participants in the control and experimental
groups.

Table 2. Characteristics of All Subjects
Characteristics
Age
60-65
66-70
71-75
76-80
80-85
Gender
Male
Female
Ethnicity
White
African American
Asian
Length of Stay (days)
Weight (kg)
Sodium Levels (mmol/L)
Pre
Post
Average Daily Sodium
Intake (mg)
Edema
Presence
Absence

n (%)
30 (100)
2 (7)
4 (13)
7 (23)
11 (37)
6 (20)

Mean ±SD
75.40 ± 6.94
NA
NA
NA
NA
NA
NA

18(60)
12(40)
NA
23(76.7)
6(20.0)
1(3.3)
30(100)
30(100)

16.07 (+5.21)
81.88 (+17.27)

30(100)
30(100)
30(100)

131.07 (+2.72)
134.37 (+3.20)
2,982.83 (±491.06)
NA

9(30)
21(70)

30

Table 3. Comorbidities
All
participants
Comorbidity
Hypertension
Diabetes
Chronic Heart
Failure
Hyperlipidemia
Hypothyroidism
Cancer
COPD

n (%)
24(80)
5(16.67)
2(6.67)

Non fluid
restriction
Gatorade®
n (%)
8(80)
2(20)
0

Non fluid
restriction
Water
n (%)
9(90)
2(20)
1(10)

Fluid
restriction
Gatorade®
n (%)
4(80)
0
0

Fluid
restriction
Water
n (%)
3(60)
1(20)
1(20)

4(13.33)
3(10)
3(10)
4(13.33)

1(10)
2(20)
1(10)
2(20)

1(10)
0
1(10)
0

1(20)
1(20)
1(20)
1(20)

1(20)
0
0
1(20)

Table 4. Sodium Intake Levels per Day
Group

n

Experimental a
Control b
Non-Restriction ab
Experimental restriction

10
10
20
5

Sodium Intake per
Day Mean ±SD
2,798.70 ± 678.21
2,575.50 ± 994.91
2,687.10 ± 836.58
3,115.40 ± 337.39

c

Control restriction d
5
3,251.60 ±769.60
Restriction cd
10
3,283.54 ± 558.63
abcd
Total
30
3,166.31±493.58
a.Gatorade® non-fluid restriction, b. Water non-fluid restriction, c. Gatorade® fluid restriction,
d. Water fluid restriction
Serum Sodium Levels
Hypothesis 1 (Elderly patients with hyponatremia on a fluid-restricted diet will have a
significantly higher serum sodium level when given Gatorade® compared to those patients on
the standard treatment protocol) was not supported. The mean post-test serum sodium level
increased significantly in all groups except the non-fluid-restricted control group. Nine of the ten
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participants from the experimental group without a fluid restriction had an increase in serum
sodium levels while the one participant’s serum levels remained unchanged. Of the participants
not in the fluid restriction control group, 60% (n=6) had increased serum sodium levels while
40% (n=4) showed no difference in their serum sodium levels from pre- to post-test study. All
ten of the participants on the fluid-restriction diet had an increase in their serum sodium levels in
the post-test.
A paired-samples t-test was conducted to determine if there was a difference in the serum
sodium levels before and after Gatorade® was used in the treatment of hyponatremia.
Participants in the fluid-restricted experimental group had a mean pre-test serum sodium level of
128.00 ±3.16mg/dl and a mean post-test serum sodium level of 132.2±1.30mg/dl (Table 5).
There was a statistically significant difference (p<0.05) in serum sodium levels between the preand post-test study for participants in the experimental fluid-restricted diet group.
Participants in the control fluid-restricted diet group had a mean pre-test serum sodium
level of 134.00 ± 3.36 mg/dl and a mean post-test serum sodium level of 134.00 ± 2.74 mg/dl
(Table 5). This was a significant difference in serum sodium levels (p<0.05).
Of the total participants on the fluid-restricted diet, the difference in the serum sodium
levels between the pre- and post-test study was also statistically significant p<0.05
(132.00±1.81mg/dl and 135.00±3.46mg/dl respectively).
Subjects not on a fluid-restricted diet in the experimental group had a mean pre-serum
sodium level of 132.00±1.83mg/dl and a mean post-test serum sodium level of 135.80±3.19
mg/dl (Table 5), which was significantly different in serum sodium level( p<0.05).
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The control group not on a fluid-restricted diet had a mean pre-test serum sodium level of
132.00±1.88 mg/dl and a mean post-serum sodium level of 134.20±3.71mg/dl (Table 5). There
was not a significant difference in serum sodium levels in this group.
Among the total participants not on a fluid-restricted diet, there was a significant
difference in the serum sodium between the pre- and post-test study (p<0.05). The mean serum
sodium levels in the pre-test for participants on a fluid restriction diet was 129.20±1.05mg/dl.,
while the mean serum sodium level in the post-test was 133.10±2.22mg/dl.
For the pre-test, serum sodium levels were significantly different between the four groups
(p<0.05). There was a significant difference in the experimental group between the experimental
fluid-restricted group and the experimental non-fluid-restricted group (p<0.05). There was also a
significant difference between the control and the experimental fluid-restricted group (p<0.05).
Participants in both the experimental and control groups had an increase in serum sodium levels.

Table 5. Serum Sodium Levels Pre- and Post-Test
Group
Experimental a
Control b
Experimental restriction

n
10
10
5

Pretest Mean ±SD
132.00±1.83
132.00±1.88
128.00±3.16

Posttest Mean ±SD
135.80±3.19
134.20±3.71
132.20±1.30

P value
0.024 ac
0.16
0.024 bc

c

Control restriction d
5
130.40±3.36
134.00±2.74
0.00
Total e
30
131.07±2.71
134.37±3.20
0.020 de
a.Gatorade® non-fluid restriction, b. Water non-fluid restriction, c. Gatorade® fluid restriction,
d. Water fluid restriction, e. Total participants
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CHAPTER 5

DISCUSSION

The purpose of the study was to determine whether using Gatorade® to treat
hyponatremia would increase serum sodium levels of subjects with a diagnosis of hyponatremia.
In this randomized experimental control study, every other subject was randomly assigned to
either the experimental or the control group, resulting in 10 subjects without a fluid restriction in
the experimental group assigned to the Gatorade® treatment and 10 to the control group without
a fluid restriction who received plain water, five subjects on a fluid restriction in the
experimental group assigned to Gatorade® five subjects on a fluid-restricted diet in the control
group receiving plain water. The subjects participated in the study for 7 days.
The results of the study found all groups had an increase in serum sodium levels after 7
days of observation. There was a significant difference over time between pre- and post-test
mean values for both the experimental and control groups in their serum sodium levels.
Although not every participant in the study had an increase in serum sodium levels, all
ten of the fluid-restricted participants had an increase in serum sodium levels. This supports the
current treatment modality of using fluid-restricted diets to increase serum sodium levels.55
There was a significant increase pre- and post-test study in serum sodium levels in both the fluidrestricted groups (experimental and control groups). These findings support current research that
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fluid-restricted diets aid in increasing serum sodium levels.55 Although some studies did not find
a significant increase in serum sodium levels, those studies were of much shorter duration and
lasted only for 72 hours. These shorter studies focused on the effects of medications on serum
sodium levels.60 The study at hand was conducted over 7 days to adequately assess the effect of
Gatorade® intake while on a fluid-restricted diet.
The difference in sodium consumed by participants may have contributed to the lack of
significant differences between serum sodium levels of experimental and control groups. The
participants in this study were not on a controlled sodium intake. The mean sodium intake for
participants on a fluid-restricted diet in the experimental group was 3,115.40 ± 337.39mg, while
the fluid-restricted participants in the control group consumed on average 3,251.60 ±769.60 mg
of sodium per day. If participants in the control group consumed more sodium than the
experimental group, their serum sodium level may have risen more. In addition, 80% of the
participants were diagnosed with hypertension and could have been on medication affecting fluid
and electrolyte balance.
A fluid-restricted diet is used to treat hyponatremia because the restriction decreases the
water in the body and increases the serum sodium concentration.13 Previous research examined
active adults (age 22-36) given isotonic beverages to prevent a decrease in serum sodium during
exercise in hot temperatures. In the current study, the majority of the participants with
hyponatremia on a fluid-restricted diet had an increase in serum sodium levels, with 90% of
those in the experimental group and 60% of the control group increasing serum sodium
concentration. The results of the current study support previous study findings that reported
participants given a beverage with sodium reduced the decline in serum sodium levels compared
to beverages without sodium.18,58
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Participants not on a fluid-restricted diet in the experimental group had a statistically
significant increase in serum sodium levels while the participants in the control group did not
have a significant increase in serum sodium levels. Gatorade® helps with hyponatremia in
athletes by replenishing the body’s stores of sodium that are depleted during exercise.16 Although
the non-fluid-restricted control group did not have a statistically significant increase in serum
sodium levels, there was not a statistically significant difference between the non-fluid-restricted
groups. This implies Gatorade® will help increase serum sodium levels over a 7-day period, but
it does not increase serum sodium levels significantly more than water. This contradicts
previous research findings using isotonic beverages to increase serum sodium levels. This may
be due to the difference in population that was studied; previous research examined active adults
age 22-36 years old exercising in heat, while the current study examined elderly hospitalized
patients age 60-85 years old.18,58
While no significant difference was found between the total experimental and control
populations on serum sodium levels in the current study, further studies of Gatorade®
consumption designed to control the sodium intake levels of participants might reveal significant
differences between the two groups. The current study demonstrated a significant difference
between pre- and post-test serum sodium levels for all fluid-restricted participants and the nonfluid-restricted experimental group. These results indicate that a fluid-restricted diet may help to
increase serum sodium levels and Gatorade® consumption on a non-fluid-restricted diet may be
useful in increasing serum sodium levels in patients with hyponatremia. This may lead to an
alternative method of treatment for patients who have hyponatremia and improve their quality of
life. Patients who do not want to be on a fluid-restricted diet may find consuming Gatorade® to
be a more palatable treatment option. The treatment of hyponatremia is important because it
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increases a patient’s length of stay. If Gatorade® could be used to increase serum sodium levels,
it may decrease the patient’s hospitalization time and save the institution money. In addition,
hyponatremia is associated with increased mortality rates; if hospitals use Gatorade® to treat
hyponatremia it may decrease the mortality rates of patients. Treating patients with hyponatremia
with Gatorade could benefit both the hospital and the patients.

Conclusion
The results of this study suggest people with hyponatremia who are not on a fluid
restriction may benefit from consuming Gatorade® to help increase their serum sodium levels.
The current study gave participants with hyponatremia who were not on a fluid-restricted diet 4
oz of Gatorade® with each meal. Gatorade® consumption may have caused their serum sodium
levels to significantly increase over a 7-day period, although the increase was not significantly
different than the control group receiving water. Although more research is needed, this may be
an alternative treatment option for patients with hyponatremia.
Moreover, hospitalized patients may also increase their serum sodium level by being put
on a fluid-restricted diet. Both the participants in the control and experimental groups who were
on a fluid-restricted diet had a significant increase in serum sodium levels. Studies have shown
quality of life is negatively affected when patients are on a fluid-restricted diet52, 53, which is why
giving Gatorade® to people with hyponatremia may be a reasonable alternative treatment option.
Patients who do not want to be on a fluid-restricted diet may find consuming Gatorade® daily to
be an easier task to achieve in order to increase their serum sodium levels. Also, hospitals may
save money by decreasing the length of stay for patients who have hyponatremia.
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CHAPTER 6

LIMITATIONS AND FUTURE RESEARCH

Limitations of the Current Study
Several limitations of this study should be noted. One limitation is the small sample size.
The recruitment process was selective, leading to lower participation rates. Completing a study
in a small hospital made it difficult to obtain a large sample size. The small sample size limited
the power of the study significance. Previous studies examining increase serum sodium levels
had funding from the pharmaceutical companies, which may explain the increased sample size.61
The current study was not funded by any company or organization.
The study was designed to examine if Gatorade® consumption increased serum sodium
levels in subjects with hyponatremia. The amount of sodium participants consumed widely
varied between subjects. Having a standard amount of sodium each participant consumed
throughout the day may have helped regulate how much sodium was being consumed.
Another limitation to the study may be the participants quality of life. Studies have
shown being on a fluid-restricted diet affects patients’ quality of life.52-53 Participants in the
fluid-restricted group may have had a decrease in their quality of life.
In addition, the lemon-lime flavor of Gatorade® was not always a favorite. A few
potential participants declined the study due to the Gatorade® flavor. Some participants became
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tired of the lemon-lime flavor of Gatorade®. If participants were given a variety of flavors to
choose from, they may have been more compliant in consuming the Gatorade®.

Recommendations for Future Study
Future studies would likely benefit from increased compliance and decreased attrition
rates if participants were given a choice of Gatorade® flavor to consume. Some participants did
not like the lemon-lime flavor. Other participants wanted more variety in their drink; they got
tired of having the same flavor beverage three times a day.
Furthermore, having participants consume similar sodium levels of food may eliminate
confounding variables in the analysis of the study. There was a wide range of intake from
sodium in foods. This may have affected the study results.
Additionally, increased sample population would allow for greater confidence in the
study findings. Having a greater sample size may show increased significant differences between
the groups. A greater sample size would increase the power to detect differences in serum
sodium levels between gender and ethnicity.
Another important factor to examine is the patient’s quality of life. Research shows a
fluid-restricted diet can decrease a patient’s quality of life. Examining wheather giving patients
Gatorade® increases their quality of life compared to patients on a fluid-restricted diet is an
important factor which should be considered.
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Amount of Fluid Provided on Patient Trays for
Fluid-restricted Diets
Fluid
Breakfast
Lunch
Supper
Daily Total from
Restriction
Meal Trays

1000 ml
1200 ml
1500 ml
1800 ml
2000 ml

1 cup (8
oz.)
1.5 cup
(12 oz.)
1.5 cup
(12 oz.)
2 cup (16
oz.)
2 cup (16
oz.)

1 cup (8
oz.)
1 cup (8
oz.)
1.5 cup
(12 oz.)
2 cup (16
oz.)
2 cup (16
oz.)

1 cup (8
oz.)
1 cup (8
oz.)
1.5 cup
(12 oz.)
1.5 cup
(12 oz.)
2 cup (16
oz.)

24 oz. (720ml)
28 oz. (840ml)
36 oz. (1080 ml)
44oz (1320 ml)
48 oz. (1440 ml)

Nursing
Fluid
Allowance
between meals
9.3
oz.(280ml)/day
12 oz.
(360ml)/day
14 oz.
(420ml)/day
16oz (480
ml)/day
18.6 oz.
(560ml)/day

Fluid Content of Beverages Served at Marianjoy
Item
Ounces (oz.)
milliliters (ml)
Carton of Milk
8 oz.
240 ml
Nectar thick Milk
8 oz.
240 ml
Orange Juice
6 oz.
180 ml
Cranberry Juice
6 oz.
180 ml
Apple Juice
6 oz.
180 ml
Prune Juice
4 oz.
120 ml
Lemonade
4 oz.
120 ml
Apricot Nectar
4 oz.
120 ml
V-8 Juice
5.5 oz.
165 ml
Nectar thick juices
4 oz.
120 ml
Nectar thick water
4 oz.
120 ml
Regular Health shakes
6 oz.
180 ml
Glucerna Shakes
8 oz.
240 ml
Soda: Cola/
8 oz.
240 ml
Lemon lime
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Gingerale
Jell-O
Ice Cream
Sherbet
Sorbet
Green Coffee or Tea Cup
Iced Tea (8 oz. cup)
Ensure Clear
Green Bowl of Soup (6 oz.
bowl)
Fruit Smoothie

8 oz.
4 oz.
4 oz.
4 oz.
4 oz.
6 oz.
6 oz.
6.8 oz.
4 oz.

240 ml
120 ml
120 ml
120 ml
120 ml
180 ml
180 ml
200 ml
120 ml

8 oz.

240 ml
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REVISION SUBMISSION FORM

Instructions: Revisions of a procedural nature, revisions that change the consent form, and
changes in risk are sent to the IRB Board for full review and should be submitted two weeks
prior to the IRB meeting. Revisions of a minor nature, e.g., minor wording changes, changes in
personnel, corrections, are reviewed administratively. Revisions may be considered by the IRB
chair to be non-substantive minor revisions to protocol procedures. If this is so determined, then
the revisions will be reviewed by the Chairperson of the MRHC/MMG IRB. All other revisions
will be reviewed by the full IRB committee at the next scheduled meeting. This form should be
used to submit revisions outside of the Periodic Review. If you are requesting a Revision as
part of the Periodic Review process this request can be included in the Periodic Review
form.
1. Submission Date: 11/10/15
2. Principal Investigator Name: Hannah Degen
Phone: 630-303-0886
Fax: None
E-Mail : hdegen@niu.edu
3. Submission Prepared By: Hannah Degen
Phone:630-303-0886
Fax:None
E-Mail : hdegen@niu.edu
4. Project Title: Using Gatorade® to Control Serum Sodium Levels of Hyponatremic Patients
on a Fluid-restricted Diet
5. Investigator Brochure (IB): IB Version Date and Number:
Does this new IB represent any changes to risks listed in the current approved consent form?
YES x NO
If new risks are described in the investigator’s brochure, a new consent form must be attached.
Additional comments can be written in the two columns below.
6. Revision Description:
6.1. This revision was initiated by: PI
Study Sponsor
If by the Study Sponsor: Protocol Amendment #
dated
6.2 Revision Type:
Please check all applicable categories:
Change in Protocol (this includes inclusion/exclusion criteria, data collection, and
recruitment)**
Change in total number of subjects
Change in investigator or other authorized personnel**
Change in consent/information documents **
Other (for example, change in title):**
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**NOTE: Revisions that may affect the Research Informed Consent And Authorization for Uses
and Disclosures of Protected Health Information for Research form.

7. Consent Form: Do the revisions require modification to the consent form(s)?
NO
Not Applicable
If yes, attached a newly revised consent form(s) with the changes highlighted.
Newly Revised Consent Form(s) Version:
Date:

YES

To aid in the review, please describe the nature of the change(s) and the rationale for change(s).
Changes to protocol or consent form should be highlighted and attached to this submission.
Revisions involving change in Authorized Personnel should reflect those changes in the
Personnel table provided below. An explanation of the role additional personnel have in the
research study should be provided in the rationale section below. Do not include a new research
proposal form. If additional information or comments are needed, please attach an additional
sheet.

PRESENT SITUATION
REQUESTED/RATIONALE
There has been an increase in the number of
patients being dehydrated at Marianjoy. To help
prevent this from happening fewer patients are
being put on a fluid restriction. Over the last two
months there has been a decrease in the number of
hyponatremic patients being put on a fluid
restriction. In order to obtain 30 participants for
the study the participant requirements need to be
changed.

REVISION
The original study required participants
to have hyponatremia and be on a fluidrestricted diet. Due to the decrease in
patients on a fluid restriction the
participants being recruited after the
protocol revision will have hyponatremia
and not be on a fluid-restricted diet.
These participants will receive 4 oz. of
either Gatorade® or water on every meal
tray (12 oz. daily). Changing the subject
requirements will allow the study to
obtain 30 participants.

Revisions to Authorized Personnel: Complete the information below for all changes to
personnel.
Name of
Role in
Phone
E-mail
Nature of
IRB
Changed
Project
Number:
address:
Personnel
Administrator
Personnel
change:
has a copy of
Addition
CITI Training
or
Certificate
Removal
Add
Yes
No
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Remove
Add

Yes

No

Remove
Add

Yes

No

Remove
Add

Yes

No

Remove

___________________________________________________
Investigator’s Name and Signature

________________
Date

After completing this form, it can be sent electronically to Renée Ecklund, IRB Administrator,
recklund@marianjoy.org Print and submit a hard copy of last page with signature.
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MJ IRB Form - Template 1

RESEARCH INFORMED CONSENT
and
AUTHORIZATION FOR USES AND DISCLOSURES OF PROTECTED HEALTH
INFORMATION FOR RESEARCH

Patient Participant:
Date:

______

Account Number: ___________________
Time: ____________

1. Title of Research Study: Using Gatorade® to control serum sodium levels of
hyponatremic patients on a fluid-restricted diet
2. Sponsor: Hannah Degen
3. Marianjoy Principal Investigator: Hannah Degen
4. Co-Investigators: None
5. Introduction:
You are being asked to volunteer to be a subject in a research study. This form is
designed to provide you with the information necessary for you to make an informed
decision regarding participation in this study.
Marianjoy Rehabilitation Hospital & Clinics /Marianjoy Medical Group (MRHC/MMG)
recognizes the valuable role that participants play in research regarding rehabilitation and
disability. To that end, MRHC/MMG is committed to protecting the safety and wellbeing of patients within our organization who participate in any research study.
The MRHC/MMG Human Subjects Institutional Review Board (IRB00004428) oversees
all research done at MRHC/MMG. The IRB stamp above indicates that this review board
has approved the study described in this consent form. As a participant in a research
study, it is important that you read this form completely. Please ask questions if you do
not understand any information presented in this form.
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6. Purpose of Research Project:
 You are being asked to participate in this research study because you are a
hyponatremic patient on a fluid-restricted diet.
 The purpose of this research study is to examine if giving Gatorade® to rehabilitation
patients on a fluid restriction with hyponatremia will increase their serum sodium
levels compared to hyponatremic patients given water.
 Your participation is expected to last one week.
 Approximately 30 people will be enrolled in the study.
7. Research Procedures: The following information describes what will happen when
you participate in this research study:
When you are given your medicine you will be given a premeasured amount of
Gatorade® or water based on your fluid restriction. In addition, you will have your blood
drawn and the sodium levels test on the first, third, and seventh day of the study. The
researcher will access your medical records to obtain demographic information and
comorbidities.
8. Risks: Participation in this study involves:
No foreseeable risks.
9. Benefits:
 The potential benefits include:
Increasing serum sodium levels through Gatorade® consumption.
 Participation in this study may aid in better understanding of:
Treatment of hyponatremia.
10. Alternatives: Participation in this study is voluntary; the alternative is to choose not to
participate.
11. Investigators Access to and Use of Protected Health Information:
Protected health information (PHI) is private information about a person’s health that
includes identifying information that would make it possible to figure out whose
information it is. The law protects this private information, and gives you the right to
decide who can see it.
If you choose to take part in this research study, the researchers (the investigators listed
above in sections 3 and 4, and their research staff individuals carrying out the study) will
access your PHI for the research described in this consent form. The researchers are
required to maintain confidentiality of your entire PHI.
The PHI that is being collected as part of this research study is demographic information
and comorbidities.
The researchers will get this PHI from the patient’s medical records.
When reviewing medical or billing records to collect the data, the researchers might see
PHI that they do not need to collect for the research study. This PHI that is
unintentionally accessed might include details about mental illness or developmental
disabilities, HIV/AIDS test results, drug/alcohol abuse, results from generic testing, or
information about sexually transmitted diseases. Any PHI that is viewed unintentionally
will not be collected or reported as part of this research study.
As soon as you sign this consent, you authorize the researchers’ access to and use of your
PHI. This authorization to access and use your PHI will expire:
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__ when the following event occurs: participant has completed the study.
However, you may ask the researchers (either verbally or in writing) to stop using your
PHI at any time. The person to notify to do this is Hannah Degen. If you tell the
researcher to stop using your PHI, your participation in the study will end and the
researchers will stop collecting new PHI from or about you. However, the researchers
will continue to use the PHI already collected up to the time they received your request
asking them to stop.
12. Access to Protected Health Information by Authorized Representatives of
MRHC/MMG or Affiliate:
If you choose to take part in this research study, other authorized representatives of
MRHC/MMG or Affiliates (in addition to the investigators/researchers as described in
section 11) might see your PHI. These persons are also required to maintain
confidentiality of your PHI and include the following:
 Authorized representatives of MRHC/MMG might see your (PHI) in order to (1)
fulfill orders associated with research study participation, and/or (2) address correct
payment for tests and procedures ordered by the investigators.
 Authorized representatives of MRHC/MMG Human Subjects Institutional Review
Board might see your PHI in order to monitor the conduct of the research study.
13. Confidentiality:
The protected health information collected for the study will be stored for research
purposes. Your information will be stored electronically and in paper form. Your
protected health information is confidential. The following physical and technical
safeguards will protect it: All records connecting your name with the protected health
information will be stored on a Marianjoy computer behind the Marianjoy firewall.
This research study might produce results related to your medical treatment. If the
research results are related to your medical treatment, then the research results will be
placed in your MRHC/MMG medical record. If the results of this study are reported in
medical journals or at meetings, you will not be identified.
In addition, parts of your PHI may be copied and sent to a central location, only after all
of your identifying information has been removed. This is then referred to as deidentified information. Your de-identified PHI may be passed on to other persons or
groups not named here.
14. Disclosure of Protected Health Information:
Your protected health information might be disclosed as required by law. Your
protected health information might be disclosed in response to an order from a court of
law. Your protected health information might also be disclosed to authorized
representatives not affiliated with MRHC/MMG including:
a. The Office for Human Research Protections (OHRP) for the purpose of ensuring
the subject’s protection.
b. The U.S. Food and Drug Administration (FDA) for the purpose of monitoring
research data accuracy.
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c. External sponsors of the research study for the purpose of monitoring research data
accuracy and for performing data analyses.
The authorized entities above are required to maintain confidentiality of your protected
health information; however, MRHC/MMG cannot guarantee the confidentiality of
information disclosed after its receipt by others.
15. Research Photographs and Videotapes:
At the end of this consent form, you will be given the option of allowing us to take
photographs and/or make videotape recordings of you. These photographs and/or
videotapes may be used in medical or scientific publications and presentations. These
photographs and/or videotapes will not be labeled with your personal information.
16. Financial Information:
There are no charges to you for any of the research procedures that you receive as
described in this form. The study sponsor will pay for all procedures that are directly
associated with this research study. Any procedures or drugs that are part of your routine
medical care for your condition will be the responsibility of you or your insurance
company.
17. Research Related Injury:
If a research related injury occurs, the investigators will address any harmful
consequences you may have experienced from research participation. The medical staff
of MRHC/MMG and any other affiliated institutions will provide immediate medical
attention for any physical injury resulting from your participation in this project. If such
medical attention is provided, MRHC/MMG and its affiliates neither admit liability nor
waive legal defense. If you are injured as a result of the research procedures, your injury
will be treated. You will be responsible for any charges related to such treatment. This
hospital makes no commitment to provide free medical care or payment for any
unfavorable outcomes resulting from participation in this research. Medical services will
be offered at the usual charge.
18. Subject’s Rights:
Participation in this study is voluntary and you are free to withdraw at any time. You
may withdraw from the study by providing a verbal or written and dated notice to the
investigator of this study Hannah Degen at hdegen@mairainjoy.org, Wheaton, IL 60187.
You are also free not to let the researchers and other groups see and share your health
information. If you choose not to be in the study or not to let the researchers and other
groups use your health information, there will be no penalties. In other words, you will
still be able to get medical treatments without being in the study and it will not affect
your eligibility for any health plan or any health plan benefits or payments for which you
may be eligible.
Marianjoy’s Notice of Privacy Practices specifies how you may access your protected
health information, including information resulting from participation in this research
study. Contact the Privacy Officer at (630) 909-8032 if you have a need to review your
protected health information collected for this study.
Any new findings developed during the course of this research that may affect your
willingness to continue will be provided to you. Participation or withdrawal will not
affect your present or future medical treatment.
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We may want to contact you after you are no longer participating in this study. We may
contact you by telephone regarding participation in additional research. You do not,
however, have to agree to participation in this additional research.
Information regarding your rights can also be obtained from the MRHC/MMG Human
Subjects Institutional Review Board Administrator at telephone number (630) 909-7140.
19. Contact Persons: If you have questions about this study at any time you can call the
Researchers at 630-303-0886 or 815-753-6351. If you have any questions about your
rights associated with the use and disclosure of protected health information for this
research study, you may contact MRHC/MMG Privacy Officer at (630) 909-8032.
Consent: I have read this form and the research study has been explained to me. I have been
given the opportunity to ask questions about my participation in this study and the use and
disclosure of my protected health information and my questions have been answered to my
satisfaction. If I have additional questions, I have been told whom to contact. I voluntarily agree
to participate in the research study described above. I authorize the collection, uses and sharing
of my protected health information as described in this form. I will receive a copy of this signed
consent form after I have signed it.
______________________________________________________________________________
_______

Printed Name of Subject
Subject’s Signature

Date

___________________________________________________________
Printed Name of Person Providing Information/Obtaining Written Consent

______________________________________________________________________________
______
Signature of Person Providing Information/Obtaining Written Consent
Date
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Hello!
My name is Hannah Degen and I am a graduate student working on my master’s degree in
Nutrition and Dietetics at Northern Illinois University. To graduate a thesis project is required
and I need your help fulfilling this part of my graduation requirements. For my thesis I am
interested in studying how Gatorade® can be used to help patients with hyponatremia meet their
fluid needs. You have been asked to participate in this study because you are on a fluid-restricted
diet because of hyponatremia.
If you decide to participate in this study, all of your fluid intake will be measured, and
you will be given a premeasured amount of Gatorade® or water based on your fluid restriction
when you are given your medicine. Your food intake will also be documented to obtain the
amount of sodium in your diet. In addition, your blood will be drawn for the sodium levels on the
first, third, and seventh day of the study. I will also use information from your medical chart to
obtain the results of the sodium blood test as well as other demographic information, weight,
pitting-edema, urine input and output. As a participant, you will remain on the study while you
are in the hospital.
This study is voluntary and you may choose to participate or not to. You may also stop
participation at any time during the study and it will not affect your treatment nor will it affect
your relationship with Marianjoy. If you have any questions about the study, please contact
Hannah Degen (e-mail:hdegen1@niu.edu) or Dr. Josephine Umoren, faculty advisor email
jxu1@niu.edu.
Thank you very much.
Sincerely,
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Marianjoy IRB Application

Submission Level:
 Full Board
Review
 Expedited Review
 Exempt

Research Proposal Application

Title of Proposed Research Study
Principal Investigator: Hannah Degen

Location:
Marianjoy
Rehabilitation
Hospital

Phone:

Co-investigators:
Date of Submission:
Projected project period:
P.I. of record and applicant institution, if consortium or subcontract:
Sponsoring agency:
Agency #, if renewal/revision:
Direct cost requested:

Indirect cost:

Location of program activity: ( List all sites, locations, etc., where subjects or data will
be recruited.)
1. Marianjoy Rehabilitation Hospital
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Purpose of Application:
New
Revision

Type of Study:
Retrospective

Vulnerable
Populations
(check all
that apply):

Prospective
Case Study
Single Subject Design

Women
Children
Cognitively
Impaired
Prisoners
Comatose
Patients
Terminally Ill
Patients
Elderly
Patients
Minorities
Students,
Employees
and/or normal
volunteers

Brief Abstract of Research Proposal: (300 word or less non-technical summary of
the research proposed including brief statement of purpose, background,
limitations and description of study design, methods and procedures.)
The purpose of this study is to examine if giving Gatorade® to rehabilitation
patients on a fluid restriction with hyponatremia will increase their serum sodium
levels compared to hyponatremic patients given water.
Hyponatremia is serum sodium levels less than 135 mmol/L. It is the most
common electrolyte disorder among hospitalized patients. Patients with
hyponatremia have significantly longer length of stay in the hospital and
increased probability of complications during their hospital stay. The increased
risk to dehydration with age places older adults at an increased risk for
hyponatremia. Older adults also tend to have impaired renal and other age-related
physiological changes which cause a decrease in fluid consumption.
Isotonic beverages may be able to help hyponatremic patients normalize serum
sodium levels. One such isotonic beverage
Gatorade®, has been used to assist athletes better control the decline in serum
sodium levels. To date there is no available research to document the effect of
Gatorade® intake on serum sodium levels among patients with hyponatremia.
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The experimental group’s Gatorade® allowance will be monitored by the study
trained nursing staff and diet technicians. Participants in the control group will be
given pre measured water from the nursing staff when they are given their
medicine based on their fluid requirements. Participants in the experimental
group will be given Gatorade® by the nursing staff when medicine is
administered. The amount of fluid given by the nurses ranges from 280 ml-560
ml/day. The Gatorade® will be measured out and labeled for each participant by
the researcher every night and stored in the prearranged refrigerator. The nursing
staff will take the pre-measured fluid out of the refrigerator and give to the
patient when they are given their medicine. Any leftover fluid will be put on a
designated cart to be measured by the researcher using a 250 ml cylinder and
record the fluid to the nearest ml on a chart. In addition the nursing staff will
leave the patients trays after meals on a designated cart.
Objectivity in Research
I have read the Wheaton Franciscan Healthcare IRB/Research policy.
Yes
No
Do you, your spouse, or dependent children, or any professional personnel listed on your
research proposal have any significant financial interest that would reasonably appear to
be affected by the research or whose financial interest would reasonably appear to be
affected by this research?
Yes

No

If yes, the principal investigator and/or appropriate professional personnel listed must
complete a Confidential Financial Disclosure Statement to be submitted with these
forms.

Funding
External funding being sought:
Yes
No

Internal funding being sought:
Yes
No
SPF #

Potential Funding Source:

Signature/Date:
SVP responsible for Special
Purpose Funds:

Do these research procedures involve (check those that apply):
Radioactive materials

Drugs

Name of drug or device:
Is this an investigational drug or device?

Investigational drugs/devices*
Yes

No
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IND/IDE #:
Sponsor or manufacturer:
NR
Is this a significant risk (SR) or nonsignificant risk (NR) device?
SR
Any FDA restrictions:
*Requires approved indemnifications of Wheaton Franciscan Healthcare, and/or Marianjoy
Rehabilitation Hospital sponsor prior to initiation of research.

List of Authorized Research Team Members
Name of
Authorized
Research
Team
Member
Hannah Degen

Phone Number

E-mail address

Role in
Project

xxx-xxx-xxx

Hdegen1@niu.edu

Primary
Researcher

IRB
Administrator
has a copy of
CITI training
Certificate
Yes
No
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

IRB Administrator Verification that all CITI program or equivocal certificates of completion
are on file for research team.
_________________________________
_______________
Name
Date

Principal Investigator’s Assurance
Subject to the approval of this project by the Institutional Review Board (IRB), I agree not to
involve human subjects in this project until I have received the IRB’s formal written approval.
I agree not to involve human subjects in this project until I have obtained the legally effective
informed consent of the subjects or their legally authorized representative. No change in the
proposal affecting human subjects or the text of the informed consent documentation will be
made without the prior written approval of the IRB. I attest that I have read and will follow all
Wheaton Franciscan Healthcare and Marianjoy Rehabilitation Hospital institutional policies
related to this research, DHHS, principles of the Belmont Report, and FDA guidelines
regarding the ethical use of human subjects in research.
Signature of Principal Investigator:_________________________________
Date:______________________
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Gatorade
GATORADE® G2 LEMON LIME - 12 fl. oz. (355 ml)
Nutrition Facts Serving Size 1 Bottle (355 mL)
Amount per Serving Calories 30
% Daily Value* Total Fat 0g 0% Sodium 160mg 7% Potassium 45mg 1% Total
Carbohydrate 7g 2% Sugars 7g Protein 0g
Not a significant source of calories from fat, saturated fat, Trans fat, cholesterol, dietary fiber,
vitamin A, vitamin C, calcium and iron. * Percent Daily Values are based on a 2,000 calorie
diet.
INGREDIENTS: WATER, SUGAR, CITRIC ACID, NATURAL FLAVOR, SALT, SODIUM
CITRATE, MONOPOTASSIUM PHOSPHATE, SUCRALOSE, ACESULFAME
POTASSIUM,YELLOW 5, BLUE 1.
Case UPC 100-52000-12463-4
Package UPC 0-52000-12463-7
Packaging 4 /6 pack
Kosher Status No
USDA Competitive Foods Compliant Yes – H
Document Updated 7/14
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Participant #:
Food Item

Amount Served

Date:
Amount remaining

